We came across a bullish thesis on Johnson & Johnson on Max Dividends’s Substack. In this article, we will summarize the ...

Johnson & Johnson (NYSE:JNJ) ranks among the Best Low Volatility Investments in December 2025. On November 25, Guggenheim ...

Johnson & Johnson stock rises on strong earnings, the Halda deal, FDA wins and an upcoming orthopedics spinoff as analysts weigh the outlook.

Last month, Johnson & Johnson surged following a well-received quarterly earnings release. Despite a sluggish start to November, a spate of positive news has since sent the healthcare stock's shares ...

The company recently announced the acquisition of a biotech with an innovative cancer treatment. Johnson & Johnson had strong Q3 results and reported an important acquisition. Johnson & Johnson 's ( ...

This company boasts a strong history of dividend growth, making it attractive for income-focused investors. Currently, the stock appears slightly undervalued, but a clear catalyst is needed for it to ...

JNJ’s stock has risen by almost 45%, whereas PFE has declined by 6%, greatly exceeding the S&P 500's 13% increase.